HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

Author's Avatar
Dec 16, 2022

Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End